

- implications on the future of cancer staging. *Surgery*. 2002;132:589–602.
16. Leiter U, Buettner PG, Eigentler TK, Garbe C. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society. *J Clin Oncol*. 2004;22:3660–7.
  17. Valera VA, Walter BA, Yokoyama N, Koyama Y, Iai T, Okamoto H, et al. Prognostic groups in colorectal carcinoma patients based on tumor cell proliferation and classification and regression tree (CART) survival analysis. *Ann Surg Oncol*. 2007;14:34–40.
  18. Zlobec I, Steele R, Nigam N, Compton CC. A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. *Clin Cancer Res*. 2005;11:5440–3.
  19. Baquerizo A, Anselmo D, Shackleton C, Chen TW, Cao C, Weaver M, et al. Phosphorus an early predictive factor in patients with acute liver failure. *Transplantation*. 2003;75:2007–14.
  20. LeBlanc M, Crowley J. A review of tree-based prognostic models. *Cancer Treat Res*. 1995;75:113–24.
  21. Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, et al. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. *Hepatol Res*. 2010;40:251–60.
  22. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. *Hepatology*. 1996;24:289–93.
  23. Segal MR, Bloch DA. A comparison of estimated proportional hazards models and regression trees. *Stat Med*. 1989;8:539–50.
  24. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology*. 2003;38:645–52.
  25. Lee SS, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. *Antivir Ther*. 2008;13(Suppl 1):9–16.
  26. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N Engl J Med*. 2009;360:1839–50.
  27. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med*. 2009;360:1827–38.
  28. Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N, et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. *Dig Dis Sci*. 2009;54:1317–24.
  29. Shiratori Y, Omata M. Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course? *J Gastroenterol Hepatol*. 2000;15(Suppl):E141–51.
  30. Gad RR, Males S, El Makhzangy H, Shouman S, Hasan A, Attala M, et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. *Liver Int*. 2008;28:1112–9.
  31. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. *J Med Virol*. 2007;79:1686–95.
  32. Males S, Gad RR, Esmat G, Abobakr H, Anwar M, Rekaewicz C, et al. Serum alpha-fetoprotein level predicts treatment outcome in chronic hepatitis C. *Antivir Ther*. 2007;12:797–803.
  33. Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. *Am J Gastroenterol*. 1998;93:2452–6.
  34. Fraser A, Ebrahim S, Smith GD, Lawlor DA. A comparison of associations of alanine aminotransferase and gamma-glutamyl-transpeptidase with fasting glucose, fasting insulin, and glycated hemoglobin in women with and without diabetes. *Hepatology*. 2007;46:158–65.
  35. Marchesini G, Avagnina S, Barantani EG, Ciccarone AM, Corica F, Dall'Aglio E, et al. Aminotransferase and gamma-glutamyl-transpeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. *J Endocrinol Invest*. 2005;28:333–9.
  36. Soresi M, Tripi S, Franco V, Giannitrapani L, Alessandri A, Rappa F, et al. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. *Liver Int*. 2006;26:1119–25.
  37. Yaginuma R, Ikejima K, Okumura K, Kon K, Suzuki S, Takei Y, et al. Hepatic steatosis is a predictor of poor response to interferon alpha-2b and ribavirin combination therapy in Japanese patients with chronic hepatitis C. *Hepatol Res*. 2006;35:19–25.
  38. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. *Hepatology*. 2001;33:1358–64.
  39. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. *J Hepatol*. 2007;46:403–10.
  40. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. *Hepatology*. 2003;37:600–9.
  41. Mazzella G, Salzetta A, Casanova S, Morelli MC, Villanova N, Miniello R, et al. Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response. *Dig Dis Sci*. 1994;39:866–70.
  42. Thomopoulos KC, Theocharis GJ, Tsamantas AC, Siagris D, Dimitropoulou D, Gogos CA, et al. Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. *Eur J Gastroenterol Hepatol*. 2005;17:149–53.
  43. Villela-Nogueira CA, Perez RM, de Segadas Soares JA, Coelho HS. Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. *J Clin Gastroenterol*. 2005;39:728–30.
  44. Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj JI, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. *Gut*. 1993;34:1714–7.

## Hepatic ISG Expression Is Associated With Genetic Variation in Interleukin 28B and the Outcome of IFN Therapy for Chronic Hepatitis C

MASAO HONDA,<sup>\*†</sup> AKITO SAKAI,<sup>\*</sup> TATSUYA YAMASHITA,<sup>\*</sup> YASUNARI NAKAMOTO,<sup>\*</sup> EISHIRO MIZUKOSHI,<sup>\*</sup> YOSHIO SAKAI,<sup>\*</sup> TARO YAMASHITA,<sup>\*</sup> MIKIKO NAKAMURA,<sup>\*</sup> TAKAYOSHI SHIRASAKI,<sup>‡</sup> KATSUHISA HORIMOTO,<sup>§</sup> YASUHITO TANAKA,<sup>||</sup> KATSUSHI TOKUNAGA,<sup>||</sup> MASASHI MIZOKAMI,<sup>#</sup> SHUICHI KANEKO,<sup>\*</sup> and the Hokuriku Liver Study Group

<sup>\*</sup>Department of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa; <sup>†</sup>Department of Advanced Medical Technology, Kanazawa University Graduate School of Health Medicine, Kanazawa; <sup>‡</sup>Biological Network Team, Computational Biology Research Center, National Institute of Advanced Industrial Science and Technology, Tokyo; <sup>§</sup>Department of Virology and Liver Unit, Nagoya City University Graduate School of Medicine, Nagoya; <sup>||</sup>Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo; and <sup>#</sup>Research Center for Hepatitis and Immunology, Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa, Japan

See related article, Younossi and Stepanova, on page 718 in *CGH*.

**BACKGROUND & AIMS:** Multiple viral and host factors are related to the treatment response to pegylated-interferon and ribavirin combination therapy; however, the clinical relevance and relationship of these factors have not yet been fully evaluated. **METHODS:** We studied 168 patients with chronic hepatitis C who received pegylated-interferon and ribavirin combination therapy. Gene expression profiles in the livers of 91 patients were analyzed using an Affymetrix genechip (Affymetrix, Santa Clara, CA). The expression of interferon-stimulated genes (ISGs) was evaluated in all samples by real-time polymerase chain reaction. Genetic variation in interleukin 28B (IL28B; rs8099917) was determined in 91 patients. **RESULTS:** Gene expression profiling of the liver differentiated patients into 2 groups: patients with up-regulated ISGs and patients with down-regulated ISGs. A high proportion of patients with no response to treatment was found in the up-regulated ISGs group ( $P = .002$ ). Multivariate logistic regression analysis showed that ISGs ( $<3.5$ ) (odds ratio [OR], 16.2;  $P < .001$ ), fibrosis stage (F1-F2) (OR, 4.18;  $P = .003$ ), and ISDR mutation ( $\geq 2$ ) (OR, 5.09;  $P = .003$ ) were strongly associated with the viral response. The IL28B polymorphism of 91 patients showed that 66% were major homozygotes (TT), 30% were heterozygotes (TG), and 4% were minor homozygotes (GG). Interestingly, hepatic ISGs were associated with the IL28B polymorphism (OR, 18.1;  $P < .001$ ), and its expression was significantly higher in patients with the minor genotype (TG or GG) than in those with the major genotype (TT). **CONCLUSIONS:** The expression of hepatic ISGs is strongly associated with treatment response and genetic variation of IL28B. The differential role of host and viral factors as predicting factors may also be present.

**Keywords:** Pegylated Interferon, Ribavirin; Gene Expression; Single Nucleotide Polymorphism.

A human liver infected with hepatitis C virus (HCV) develops chronic hepatitis, cirrhosis, and, in some instances, hepatocellular carcinoma.<sup>1</sup> Interferon (IFN) and ribavirin (RBV) combination therapy is a popular modality for treating patients with chronic hepatitis C (CH-C); approximately 50% of patients usually relapse, particularly those with HCV genotype 1b and a high viral load.<sup>2,3</sup> Therefore, it is beneficial to predict the response of patients with the 1b genotype and a high viral load to pegylated-IFN (Peg-IFN) and RBV combination therapy before starting treatment because therapy can be long, costly, and have many adverse effects. Amino acid (aa) substitutions in the interferon sensitivity determining region (ISDR), located in the HCV nonstructural region 5A, are useful for predicting the response of patients with genotype 1b to IFN therapy.<sup>4</sup> However, viral factors alone do not sufficiently predict the outcome of treatment in every case.<sup>5</sup>

In addition to viral factors, hepatic gene expression before and during IFN treatment has been examined to determine host factors associated with the response to treatment.<sup>6,7</sup> Interferon-stimulated genes (ISGs) up-regulated in the liver prior to treatment might be related to the poor induction of ISGs and the impaired eradication of HCV during treatment.<sup>6-9</sup> This may be because the ISGs have already been maximally induced before treat-

*Abbreviations used in this paper:* aa, amino acid; AST, aspartate aminotransferase; cDNA, complementary DNA; CH-C, chronic hepatitis C; Down-ISGs, down-regulated ISGs; EVR, early virologic response; GWAS, genome-wide association studies; HCV, hepatitis C virus; IFN, interferon; IFI44, interferon-induced protein 44; IFIT1, interferon-induced protein with tetratricopeptide repeats 1; IL, interleukin; IL28B, interleukin 28B; ISDR, interferon sensitivity determining region; ISGs, interferon stimulated genes; Mx1, myxovirus (influenza virus) resistance 1 interferon-inducible protein p78 (mouse); NR, no response; Peg, pegylated; RBV, ribavirin; ROC, receiver operating characteristic; RTD, real-time detection; PCR, polymerase chain reaction; RTD-PCR, real-time detection-polymerase chain reaction; SNP, single nucleotide polymorphism; SVR, sustained viral response; TR, transient response; Up-ISGs, up-regulated ISGs.

© 2010 by the AGA Institute  
0016-5085/\$36.00

doi:10.1053/j.gastro.2010.04.049

ment. However, the clinical relevance of the expression of ISGs as predictive factors for the outcome of treatment has not yet been fully evaluated.

In parallel to gene expression analysis, genome-wide association studies (GWAS) have been used to identify loci associated with the response to treatment; genetic variation in interleukin 28B (IL28B) was found to predict hepatitis C treatment-induced viral clearance.<sup>10-12</sup>

In this study, with a relatively large cohort of CH-C patients treated with Peg-IFN and RBV, we validated the clinical relevance of the expression of hepatic ISGs as predictive factors for the outcome of treatment. In addition,

we demonstrated that the expression of hepatic ISGs was closely related to genetic variation in IL28B.

## Materials and Methods

### Patients

We enrolled 168 patients with CH-C at the Graduate School of Medicine, Kanazawa University Hospital and its related hospitals, Japan (Table 1, Supplementary Table 1). The cohort included 92 men and 76 women, ranging from 21 to 73 years of age, who were registered prospectively in 2005 and 2007. All patients had HCV

**Table 1.** Comparison of Clinical Factors Between Patients With and Without NR

| Clinical category                         | SVR+TR        |               | NR        |             | Univariate<br>P value | Multivariate odds<br>(95% CI) | Multivariate<br>P value |
|---|---------------|---------------|-----------|-------------|-----------------------|-------------------------------|-------------------------|
| No. of patients                           | n = 125       |               | n = 43    |             |                       | —                             |                         |
| Age and sex                               |               |               |           |             |                       |                               |                         |
| Age, y                                    | 57            | (30–72)       | 56        | (30–73)     | .927                  | —                             |                         |
| Sex (M vs F)                              | 68 vs 57      |               | 24 vs 19  |             | .872                  | —                             |                         |
| Liver factors                             |               |               |           |             |                       |                               |                         |
| F stage (F1-2 vs F3-4)                    | 95 vs 30      |               | 20 vs 23  |             | .001                  | 4.18 (1.61–11.5)              | .003                    |
| A grade (A0-1 vs A2-3)                    | 68 vs 57      |               | 19 vs 24  |             | .248                  | —                             |                         |
| ISGs (Mx, IFI44, IFIT1)<br>(<3.5 vs ≥3.5) | 103 vs 22     |               | 12 vs 31  |             | <.001                 | 16.2 (6.21–47.8)              | <.001                   |
| Laboratory parameters                     |               |               |           |             |                       |                               |                         |
| HCV-RNA (KIU/mL)                          | 2300          | (126–5000)    | 1930      | (140–5000)  | .725                  | —                             |                         |
| BMI (kg/m <sup>2</sup> )                  | 23.2          | (16.3–34.7)   | 23.4      | (19.5–40.6) | .439                  | —                             | .107                    |
| AST (IU/L)                                | 46            | (18–258)      | 64        | (21–283)    | .017                  | —                             |                         |
| ALT (IU/L)                                | 60            | (16–376)      | 82        | (18–345)    | .052                  | —                             |                         |
| γ-GTP (IU/L)                              | 36            | (4–367)       | 75        | (26–392)    | <.001                 | —                             |                         |
| WBC (/mm <sup>3</sup> )                   | 4800          | (2100–11,100) | 4800      | (2500–8200) | .551                  | —                             |                         |
| Hb (g/dL)                                 | 14            | (9.3–16.6)    | 14.4      | (11.2–17.2) | .099                  | —                             |                         |
| PLT (×10 <sup>4</sup> /mm <sup>3</sup> )  | 15.7          | (7–39.4)      | 15.2      | (7.6–27.8)  | .378                  | —                             |                         |
| TG (mg/dL)                                | 98            | (30–323)      | 116       | (45–276)    | .058                  | —                             |                         |
| T-Chol (mg/dL)                            | 167           | (90–237)      | 160       | (81–214)    | .680                  | —                             |                         |
| LDL-Chol (mg/dL)                          | 82            | (36–134)      | 73        | (29–123)    | .019                  | —                             |                         |
| HDL-Chol (mg/dL)                          | 42            | (20–71)       | 47        | (18–82)     | .098                  | —                             |                         |
| FBS (mg/dL)                               | 94            | (60–291)      | 96        | (67–196)    | .139                  | —                             |                         |
| Insulin (μU/mL)                           | 6.6           | (0.7–23.7)    | 6.8       | (2–23.7)    | .039                  | —                             |                         |
| HOMA-IR                                   | 1.2           | (0.3–11.7)    | 1.2       | (0.4–7.2)   | .697                  | —                             |                         |
| Viral factors                             |               |               |           |             |                       |                               |                         |
| ISDR mutations ≤1 vs ≥2                   | 80 vs 44      |               | 34 vs 9   |             | .070                  | 5.09 (1.69–17.8)              | .003                    |
| Treatment factors                         |               |               |           |             |                       |                               |                         |
| Total dose administered                   |               |               |           |             |                       |                               |                         |
| Peg-IFN (μg)                              | 3840          | (960–7200)    | 3840      | (1920–2880) | .916                  | —                             |                         |
| RBV (g)                                   | 202           | (134–336)     | 202       | (36–336)    | .531                  | —                             |                         |
| Achieved administration rate              |               |               |           |             |                       |                               |                         |
| Peg-IFN (%)                               |               |               |           |             |                       |                               |                         |
| ≥80%                                      | 84            |               | 28        |             | .975                  | —                             |                         |
| <80%                                      | 42            |               | 14        |             |                       |                               |                         |
| RBV (%)                                   |               |               |           |             |                       |                               |                         |
| ≥80%                                      | 76            |               | 24        |             | .745                  | —                             |                         |
| <80%                                      | 50            |               | 18        |             |                       |                               |                         |
| Achievement of EVR                        | 101/125 (81%) |               | 0/43 (0%) |             | <.001                 | —                             |                         |

BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IFI44, interferon-induced protein 44; IFIT1, interferon-induced protein with tetratricopeptide repeats 1; EVR, early virologic response; γ-GTP, γ-glutamyl transpeptidase; ISDR, interferon sensitivity determining region; Mx1, myxovirus (influenza virus) resistance 1 interferon-inducible protein p78 (mouse); WBC, leukocytes; HOMA-IR, homeostasis model assessment of insulin resistance; Hb, hemoglobin; RBV, ribavirin; PLT, platelets; TG, triglycerides; TR, transient response; T-chol, total cholesterol; LDL-chol, low-density lipoprotein cholesterol; HDL-chol, high-density lipoprotein cholesterol; FBS, fasting blood sugar; CI, confidence interval.

genotype 1b and high viral loads ( $\geq 100\text{K IU/mL}$ ) measured by quantitative Cobas Amplicor assays (Roche Diagnostics Co Ltd, Tokyo, Japan). All patients had undergone liver biopsy before combination therapy. Exclusion criteria for patients not eligible for Peg-IFN and RBV combination therapy were as follows: (1) pregnant women or women of childbearing potential, nursing mothers, or male patients whose partner might become pregnant; (2) patients with hepatocellular carcinoma; (3) patients with serious complications in the heart, kidneys, or lungs; (4) patients with autoimmune diseases, such as autoimmune hepatitis, and primary biliary cirrhosis; and (5) patients infected with the hepatitis B virus. Informed consent was obtained from all patients, and ethics approval for the study was obtained from the Ethics Committee for Human Genome/Gene Analysis Research at Kanazawa University Graduate School of Medical Science.

All patients were administered Peg-IFN- $\alpha$  2b (Schering-Plough KK, Tokyo, Japan) and RBV combination therapy for 48 weeks. Peg-IFN was given in weekly doses and adjusted to body weight according to the manufacturer's instructions (45 kg or less, 60  $\mu\text{g/dose}$ ; 46–60 kg, 80  $\mu\text{g/dose}$ ; 61–75 kg, 100  $\mu\text{g/dose}$ ; 76–90 kg, 120  $\mu\text{g/dose}$ ; and 91 kg or more, 150  $\mu\text{g/dose}$ ). Similarly, RBV (Schering-Plough KK) was administered in daily doses adjusted to body weight according to the manufacturer's instructions (60 kg or less, 600 mg/day; 61–80 kg, 800 mg/day; and 81 kg or more, 1000 mg/day).

The final outcome of treatment was assessed 24 weeks after the cessation of combination therapy. We defined treatment outcomes according to the decrease in viremia as follows: sustained viral response (SVR), clearance of HCV viremia 24 weeks after the cessation of therapy; transient response (TR), no detectable HCV viremia at the cessation of therapy but relapsed during the follow-up period; and no response (NR), HCV viremia detected at the cessation of therapy. An early virologic response (EVR) (complete EVR) was defined as undetectable HCV-RNA in the serum by 12 weeks. HCV genotypes were determined according to the method of Okamoto et al. Serum HCV RNA was determined using qualitative and quantitative COBAS Amplicor assays (Roche Diagnostics Co, Ltd, Tokyo, Japan). The grading and staging of chronic hepatitis were histologically assessed according to the method of Desmet et al (Table 1).<sup>13</sup>

### **Preparation of Liver Tissue Samples**

Liver biopsy samples were taken from all patients before treatment. The biopsy samples were divided into 2 parts: the first part was immersed in formalin for histologic assessment, and the second was immediately immersed in RNAlater (QIAGEN, Valencia, CA) for RNA isolation. Liver tissue RNA was isolated using the RNeasy Mini kit (QIAGEN) according to the manufacturer's instructions. Isolated RNA was stored at  $-70^\circ\text{C}$  until use.

### **Affymetrix Genechip Analysis**

The quality of the isolated RNA was estimated after electrophoresis using an Agilent 2001 Bioanalyzer (Agilent, Santa Clara, CA). Aliquots of total RNA (50 ng) isolated from the liver biopsy specimens were subjected to amplification using the WT-Ovation Pico RNA Amplification System (NuGen, San Carlos, CA) according to the manufacturer's instructions. Approximately 10  $\mu\text{g}$  of complementary DNA (cDNA) was amplified from 50 ng of total RNA, and 5  $\mu\text{g}$  of cDNA was used for fragmentation and biotin labeling using the FL-Ovation cDNA Biotin Module V2 (NuGen) according to the manufacturer's instructions. Biotin-labeled cDNA was suspended in 220  $\mu\text{L}$  of hybridization cocktail (NuGen), and 200  $\mu\text{L}$  was used for hybridization to the Affymetrix Human 133U Plus 2.0 GeneChip (Affymetrix, Santa Clara, CA) containing 54,675 probes. After stringent washing, the microarray chips were stained with streptavidin-phycoerythrin, and probe hybridization was determined using a GeneChip Scanner 3000 (Affymetrix). Data files (CEL) were obtained using the GeneChip Operating Software 1.4 (Affymetrix).

### **Hierarchical Clustering and Pathway Analysis of Genechip Data**

Genechip data analysis was performed using BRB-Array Tools (<http://linus.nci.nih.gov/BRB-ArrayTools.htm>). The data were log transformed, normalized, centered, and applied to the average linkage hierarchical clustering with centered correlation.

For genechip analysis, we selected 37 representative ISGs. Hepatic gene expression profiling was obtained from 30 CH-C patients before and 1 week after the initiation of IFN and RBV combination therapy and the 100 most up-regulated genes were selected (submitted for publication). ISGs were suppressed in patients with a rapid viral response and up-regulated in patients with a slow viral response before treatment. Using the 100 treatment-induced genes, we evaluated hepatic gene expression in 30 patients before treatment. Hierarchical clustering analysis showed that a cluster of 37 ISGs was up-regulated in patients with a slow viral response.

Pathway analysis was performed using MetaCore (GeneGo, St. Joseph, MI). Functional ontology enrichment analysis was performed to compare the gene ontology process distribution of differentially expressed genes ( $P < .01$ ).

### **Quantitative Real-time Detection-Polymerase Chain Reaction**

We performed quantitative real-time detection (RTD)-polymerase chain reaction (PCR) (RTD-PCR) using TaqMan Universal Master Mix (PE Applied Biosystems, Carlsbad, CA). Primer pairs and probes for myxovirus (influenza virus) resistance 1 interferon-inducible protein p78 (mouse) (Mx1), 2'-5'-oligoadenylate synthetase 3 (OAS3), interferon-induced protein 44 (IFI44),

interferon-induced protein 44-like (IFI44L), 2'-5'-oligoadenylate synthetase 2 (OAS2), ubiquitin specific peptidase 18 (USP18), radical S-adenosyl methionine domain containing 2 (RSAD2), interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), interferon induced with helicase C domain 1 (IFIH1), XIAP associated factor 1 (XAF1), cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial (CMPK2), epithelial stromal interaction 1 (EPSTI1), hect domain and RLD 6 (HERC6), poly (ADP-ribose) polymerase family, member 9 (PARP9), phospholipid scramblase 1 (PLSCR1), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were obtained from the TaqMan assay reagents library. Primer pairs and probes for IL28B were designed as previously described.<sup>12</sup> The standard curve was obtained in every assay using the RNA obtained from a normal liver.<sup>14,15</sup> The expression values were normalized by GAPDH, and normalized values indicate the relative fold expression to a normal liver.

#### ***Amino Acid Substitutions of ISDR in the Nonstructural 5A Region***

The nucleotide sequence of ISDR in the nonstructural 5A region was determined by direct sequencing of PCR amplified materials.<sup>4</sup> Mutant-type ISDR was defined as containing 2 or more aa substitutions.

#### ***Genetic Variation of IL28B Polymorphism***

A single nucleotide polymorphism (SNP) of IL28B was evaluated in 91 patients whose hepatic gene expression profiling was obtained. We genotyped 32 patients using Affymetrix Genome-Wide Human SNP Array 6.0 as previously described.<sup>12</sup> The results for rs8105790, rs11881222, rs8099917, and rs7248668 were retrieved from a database to evaluate the association of these SNPs. rs12979860 was determined by direct sequencing, and rs8099917 was determined using TaqMan Pre-Designed SNP Genotyping Assays (PE Applied Biosystems) as recommended by the manufacturer.

#### ***Statistical Analysis***

The Mann-Whitney *U* test was used to analyze continuous variables. Fisher exact test and  $\chi^2$  test were used for the analysis of categorical data. The overall plausibility of the treatment response groups was assessed using Fisher C statistic (Supplementary Table 2).<sup>16,17</sup> C is defined by  $C = -2 \sum \ln(p_i)$ , where  $p_i$  is the probability (*P* value) of each independent statement (clinical factors). C follows a  $\chi^2$  distribution with  $2k$  degrees of freedom,  $k$  being the number of independent statements (clinical factors).<sup>16</sup> A nonsignificant C value means that the treatment response in the 2 groups was not statistically independent.

Multivariate analysis was performed using a stepwise logistic regression model. Each cut-off point for the continuous variables was decided by analysis of the receiver operating characteristic (ROC) curve. A *P* value of less than .05 was considered significant. Statistical analyses were performed using JMP7 for Windows (SAS Institute, Cary, NC).

## **Results**

### ***Response Rate and Clinical Characteristics***

The clinical characteristics of the patients are shown in Table 1 and Supplementary Table 1. All of the patients were infected with HCV genotype 1b and had a high viral load (>100K IU/mL). No patients were coinfecting with the hepatitis B virus (HBV). The intention-to-treat analysis showed that SVR, TR, and NR were observed in 70 (42%), 55 (33%), and 43 (25%) patients, respectively (Supplementary Table 1). Before comparing patients with 3 different responses, the overall plausibility of the treatment response groups was assessed using Fisher C statistic. Fisher C statistic utilizes the *P* values obtained by comparing pretreatment factors including age, gender, liver factors, laboratory parameters, and viral factors. Because the SVR and TR groups could not be defined as different, they were grouped together and compared with NR (Table 1, Supplementary Table 2).

Eleven patients with NR discontinued the therapy after 24 weeks because of an insufficient effect, namely, serum HCV-RNA was still detectable at this time. The remaining patients completed 48 weeks of Peg-IFN and RBV combination therapy. The administration rate of Peg-IFN with 80% or more was achieved in 67% of patients, and the administration rate of RBV with 80% or more was achieved in 60% of patients (Table 1).


### ***Analysis of Hepatic Gene Expression***

Prior to treatment, 91 of 168 patients (Supplementary Table 3) were randomly selected, and their hepatic gene expression was determined using Affymetrix genechip analysis.

Hierarchical clustering using 37 representative ISGs (see Materials and Methods) demonstrated 2 clear clusters of patients: one was a group composed of patients with up-regulated ISGs (Up-ISGs), and the other was a group consisting of patients with down-regulated ISGs (Down-ISGs) (Figure 1). In patients with Up-ISGs, 21 (49%) showed NR, whereas 8 (17%) patients with Down-ISGs showed NR ( $P = .002$ ). In contrast, 14 (33%) patients with Up-ISGs showed SVR, whereas 27 (56%) patients with Down-ISGs showed SVR ( $P = .03$ ). There were no significant differences in the frequency of advanced stages of liver fibrosis (F3-F4) between patients with Up-ISGs and patients with Down-ISGs (18 [42%] and 17 [35%], respectively,  $P = .664$ ). These data indicated that the up-regulation of ISGs in the liver before treatment was strongly associated with resistance to IFN treatment.

### ***Host and Viral Factors Associated With the Response to Combination Therapy***

To evaluate the multiple host and viral factors associated with the response to Peg-IFN and RBV combination therapy in all patients, univariate and multivariate analyses were performed. To assess the expression of hepatic ISGs, 15 genes (Mx1, OAS3, IFI44, IFI44L, OAS2,



**Figure 1.** Hierarchical clustering analysis of 91 patients using 37 representative ISGs. Responses to therapy (SVR, TR, and NR), fibrosis stage (F1–F4), and status; ISDR mutations are also shown. ISDR mutation  $\geq 2 = M$ ,  $\leq 1 = 0$ .

USP18, RSAD2, IFIT1, IFIH1, XAF1, CMPK2, EPSTI1, HERC6, PARP9, and PLSCR1) out of 37 representative ISGs were selected for their expression values of probe intensity, and their expression was confirmed in liver tissue obtained from 168 patients by RTD-PCR. Although there were significant correlations of their expression with each other, except RARP9 and PLSCR1 (Supplementary Table 4), the dynamic range of gene expression was high for 3 genes, namely, Mx1, IFI44, and IFIT1 (Supplementary Figure 1A). We averaged the expression values of Mx1, IFI44, and IFIT1 and used them for further study.

When we compared patients with SVR+TR and NR, the fibrosis stage of the liver ( $P = .001$ ), expression of hepatic ISGs ( $P < .001$ ), aspartate aminotransferase (AST) serum level ( $P = .017$ ),  $\gamma$ -glutamyl transpeptidase ( $\gamma$ -GTP) ( $P < .001$ ), low-density lipoprotein cholesterol (LDL-Chol) ( $P = .019$ ), and insulin ( $\mu\text{U/mL}$ ) ( $P = .039$ ) were significantly different prior to treatment (Table 1). For treatment factors, the total dose and administration of IFN and RBV were not significantly different between these 2 groups. EVR was observed in 101 (81%) patients, and the proportion was significantly different ( $P < .001$ ) between patients with SVR+TR and NR (Table 1).

Regression analysis of pretreatment factors showed a strong correlation among  $\gamma$ -GTP, alanine aminotransferase (ALT), and aspartate aminotransferase (AST); and homeostasis model assessment-insulin resistance (HOMA-IR), fasting blood sugar, and insulin; and total cholesterol (T-Chol), high-density lipoprotein cholesterol (HDL-Chol), and LDL-Chol (data not shown). We se-

lected fibrosis stage, ISGs, HCV-RNA, ISDR mutation, and body mass index (BMI) as factors for multivariate analysis. Stepwise multivariate logistic regression analysis was performed using the selected factors. From the ROC curve, we set the cut-off value for the expression of ISGs as 3.5 (Supplementary Figure 1B). The results showed that expression of hepatic ISGs ( $< 3.5$ ), fibrosis stage (F1-F2), and ISDR mutation ( $\geq 2$ ) were significant pretreatment factors contributing to SVR+TR (Table 1).

### Clinical Parameters Associated With the Expression of Hepatic ISGs

Univariate and multivariate analyses revealed that the expression of hepatic ISGs was a strong predictor of the treatment outcome for SVR+TR patients. We next examined which clinical parameters were associated with the expression of hepatic ISGs (Table 2). Univariate analysis showed that the expression of ISGs was strongly correlated with the serum levels of  $\gamma$ -GTP ( $P < .001$ ) and AST ( $P < .001$ ) and weakly correlated with HCV-RNA, fasting blood sugar, insulin, HOMA-IR, triglyceride (TG), and LDL-Chol. Multivariate analysis showed that  $\gamma$ -GTP ( $P < .001$ ), HCV-RNA ( $P < .001$ ), and LDL-Chol ( $P = .048$ ) were significantly associated with hepatic ISGs. Noticeably, the expression of ISGs was negatively correlated with HCV-RNA in SVR+TR patients ( $P = .009$ ), whereas this correlation was not evident in NR patients ( $P = .298$ ) (Table 2, Supplementary Figure 2). These results may indicate that endogenous ISGs suppress HCV in SVR+TR patients, whereas they are not active in NR patients.

**Table 2.** Clinical Factors Associated With Expression of Hepatic Interferon-Stimulated Genes

| Clinical factor       | Univariate analysis |        |       | Multivariate analysis |         |        |       |           |
|-----------------------|---------------------|--------|-------|-----------------------|---------|--------|-------|-----------|
|                       | $\beta$             | 95% CI |       | $P$ value             | $\beta$ | 95% CI |       | $P$ value |
| AST (IU/L)            | 0.274               | 0.13   | 0.42  | <.001                 | —       | —      | —     | —         |
| $\gamma$ -GTP (IU/L)  | 0.326               | 0.18   | 0.47  | <.001                 | 0.288   | 0.14   | 0.43  | <.001     |
| HCV-RNA (KIU/mL)      | -0.170              | -3.19  | -0.02 | .025                  | -0.255  | -0.40  | -0.11 | <.001     |
| SVR+TR                | -0.237              | -0.32  | -0.05 | .009                  | —       | —      | —     | —         |
| NR                    | -0.168              | -0.57  | 0.18  | .298                  | —       | —      | —     | —         |
| FBS (mg/dL)           | 0.182               | 0.03   | 0.35  | .021                  | —       | —      | —     | —         |
| Insulin ( $\mu$ U/mL) | 0.190               | 0.03   | 0.34  | .016                  | —       | —      | —     | —         |
| HOMA-IR               | 0.181               | 0.03   | 0.33  | .017                  | —       | —      | —     | .073      |
| TG (mg/dL)            | 0.201               | 0.05   | 0.35  | .011                  | —       | —      | —     | .089      |
| LDL-Chol (mg/dL)      | -0.177              | -0.33  | -0.02 | .025                  | -0.143  | -0.28  | 0.00  | .048      |

$\gamma$ -GTP,  $\gamma$ -glutamyl transpeptidase; AST, aspartate aminotransferase; FBS, fasting blood sugar; TG, triglycerides; TR, transient response; NR, no response; SVR, sustained viral response; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-cholesterol, low-density lipoprotein cholesterol; CI, confidence interval;  $\beta$ ,  $\beta$  coefficient; CI, confidence interval.

### Expression of Hepatic ISGs Before Treatment Is Associated With Genetic Variation of IL28B

Recently, a GWAS successfully identified the genomic locus associated with the treatment response to Peg-IFN and RVB combination therapy for CH-C. Genetic variation in IL28B predicts HCV treatment-induced viral clearance.<sup>11,12</sup> We determined the genetic variation in IL28B of 32 patients<sup>12</sup> (Table 3). The SNPs rs8105790, rs11881222, rs8099917, and rs7248668 had a significant association with treatment response (odds ratio: 24.7–27.1,  $P = 1.84 \times 10^{-30}$ – $2.68 \times 10^{-32}$ ). These SNPs are located in block 2 of the IL28B haplotype and show significant linkage disequilibrium in the HapMap data.<sup>12</sup> Ge et al<sup>11</sup> reported a different SNP (rs12979860) that was located between rs11881222 and rs8099917. The nucleotide sequence of rs12979860 was determined by direct sequencing, and the results are shown in Table 3. There was a strong association of rs12979860 and the other 4 SNPs indicating that this SNP was located within the same haplotype block. We confirmed these findings in multiple samples from Japanese patients (data not shown).

We selected rs8099917 for further study and evaluated it using TaqMan Pre-Designed SNP Genotyping Assays. The G nucleotide of rs8099917 was associated with a poor response to treatment (minor allele), whereas the T was associated with a fair response to treatment (major allele).<sup>12</sup> Out of 91 patients (Supplementary Table 3), the proportion of major homozygotes (TT), heterozygotes (TG), and minor homozygotes (GG) were 66% (60/91), 30% (27/91), and 4% (4/91), respectively (Table 4); 86% (51/60) of the major genotype (TT) patients had SVR or TR, whereas 65% (20/31) with the minor genotypes (TG or GG) had NR ( $P < .001$ ).

Interestingly, hepatic gene expression profiles revealed that patients with the minor genotype showed higher expression of hepatic ISGs, whereas patients with the major genotype showed lower expression of hepatic ISGs (Figures 2 and 3). To examine further the relationship of the genetic variation in IL28B and its expression levels, we evaluated the expression of IL28B in the liver by RTD-PCR (Figure 3). IL28B expression

was approximately 10-fold less than the expression of ISGs. Although IL28B expression tended to be higher in some patients with the major genotype, there was no significant difference in IL28B expression in the liver between the major and minor genotypes (Figure 3A). Nevertheless, the expression of ISGs was clearly high in patients with the minor genotype ( $P < .0001$ ) (Figure 3B). IL28 activates signal transducers and activators of transcription 1 (STAT1) through downstream signaling from a heterodimeric class II cytokine receptor that consists of IL-10 receptor  $\beta$  (IL-10R $\beta$ ) and IL-28 receptor  $\alpha$  (IL-28R $\alpha$ ).<sup>18,19</sup> Therefore, we examined the correlation between the expression of IL28B and ISGs. IL28B expression correlated with the expression of ISGs ( $r = 0.44$ ,  $P < .001$ ); however, the correlation was different according to the SNP genotype. We observed a steep-slope correlation for the minor genotype and a slow-slope correlation for the major genotype (Figure 3C and D). Interestingly, 4 minor homozygotic (GG) patients showed a steeper correlation than the heterozygotes (TG) (Figure 3D). Thus, the IL28B polymorphism might differentially regulate the expression of ISGs in the liver, leading to the different treatment outcomes.

We performed univariate and multivariate analyses to identify the clinical factors associated with the major and minor genotypes (Table 4). Univariate analysis showed that higher hepatic ISGs and lower body mass index were significantly associated with the minor genotype; however, multivariate analysis showed that only hepatic ISGs ( $\geq 3.5$ ) were associated with the minor genotype ( $P < .001$ ; OR, 18.1; 95% confidence interval: 3.95–113). We further compared the predictive capacity of multivariate models using the expression of hepatic ISGs ( $< 3.5$  vs  $\geq 3.5$ ) or the IL28B genotype (major vs minor) (Supplementary Table 6). The predictive performance and fitness of the multivariate model using the IL28B genotype was superior to that using the expression of hepatic ISGs. However, when these factors were included in the same model, the expression of hepatic ISGs was still useful for the predictive model independent of the IL28B genotype (Supplementary Table 6).

**Table 3.** Clinical Characteristics of 32 Patients Genotyped by GWAS and 5 SNPs in Strong Linkage Disequilibrium With IL28B,<sup>11</sup> Including rs12979860

| Patient No. | Response | Age, y     |            | F stage | ISGs | IL28B | RefSNP (chr pos) Minor allele | rs8105790  | rs11881222 | rs12979860 | rs8099917 | rs7248668 |
|-------------|----------|------------|------------|---------|------|-------|-------------------------------|------------|------------|------------|-----------|-----------|
|             |          | (44424341) | (44426763) |         |      |       |                               | (44430627) | (44435005) | (44435661) |           |           |
|             |          |            |            |         |      |       |                               | C          | G          | T          | G         | A         |
| 1           | SVR      | 42         | M          | 1       | 4.20 | 83.8  |                               | TT         | AA         | CC         | TT        | GG        |
| 2           | SVR      | 59         | M          | 1       | 2.62 | 45.5  |                               | TT         | AA         | CC         | TT        | GG        |
| 3           | SVR      | 41         | F          | 1       | 1.54 | 1.3   |                               | TT         | AA         | CC         | TT        | GG        |
| 4           | TR       | 57         | M          | 1       | 3.18 | 21.7  |                               | TT         | AA         | CC         | TT        | GG        |
| 5           | TR       | 68         | F          | 1       | 1.43 | 20.3  |                               | TT         | AA         | CC         | TT        | GG        |
| 6           | SVR      | 44         | M          | 1       | 0.97 | 4.6   |                               | TT         | AA         | CC         | TT        | GG        |
| 7           | SVR      | 61         | M          | 2       | 2.15 | 6.1   |                               | TT         | AA         | CC         | TT        | GG        |
| 8           | SVR      | 50         | M          | 2       | 3.25 | 66.4  |                               | TT         | AA         | CC         | TT        | GG        |
| 9           | SVR      | 49         | M          | 2       | 1.25 | ND    |                               | TT         | AA         | CC         | TT        | GG        |
| 10          | TR       | 59         | F          | 2       | 1.29 | 17.4  |                               | TT         | AA         | CC         | TT        | GG        |
| 11          | SVR      | 48         | F          | 2       | 1.00 | 90.2  |                               | TT         | AA         | CC         | TT        | GG        |
| 12          | TR       | 65         | F          | 2       | 2.86 | 36.4  |                               | TT         | AA         | CC         | TT        | GG        |
| 13          | NR       | 34         | M          | 3       | 0.82 | 17.8  |                               | TT         | AA         | CC         | TT        | GG        |
| 14          | SVR      | 55         | M          | 3       | 0.83 | 13.8  |                               | TT         | AA         | CC         | TT        | GG        |
| 15          | TR       | 68         | M          | 3       | 0.75 | 20.6  |                               | TT         | AA         | CC         | TT        | GG        |
| 16          | SVR      | 64         | M          | 3       | 0.94 | 15.7  |                               | TT         | AA         | CC         | TT        | GG        |
| 17          | SVR      | 67         | F          | 3       | 1.50 | 25.7  |                               | TT         | AA         | CC         | TT        | GG        |
| 18          | SVR      | 48         | M          | 4       | 1.69 | 7.9   |                               | TT         | AA         | CC         | TT        | GG        |
| 19          | NR       | 66         | F          | 1       | 4.57 | 16.5  |                               | TC         | AG         | CT         | TG        | GA        |
| 20          | SVR      | 52         | F          | 1       | 5.23 | 29.3  |                               | TC         | AG         | CT         | TG        | GA        |
| 21          | NR       | 55         | F          | 1       | 8.25 | 57.2  |                               | TC         | AG         | CT         | TG        | GA        |
| 22          | SVR      | 49         | F          | 1       | 5.36 | ND    |                               | TC         | AG         | CT         | TG        | GA        |
| 23          | TR       | 44         | M          | 1       | 2.08 | 7.0   |                               | TC         | AG         | CT         | TG        | GA        |
| 24          | NR       | 63         | M          | 1       | 2.77 | 10.5  |                               | TC         | AG         | CT         | TG        | GA        |
| 25          | NR       | 61         | F          | 2       | 3.98 | 39.1  |                               | TC         | AG         | CT         | TG        | GA        |
| 26          | NR       | 42         | M          | 2       | 4.89 | 5.9   |                               | TC         | AG         | CT         | TG        | GA        |
| 27          | SVR      | 49         | M          | 3       | 3.31 | 6.9   |                               | TC         | AG         | CT         | TG        | GA        |
| 28          | TR       | 71         | F          | 3       | 5.53 | 27.3  |                               | TC         | AG         | CT         | TG        | GA        |
| 29          | TR       | 63         | M          | 3       | 3.40 | 33.5  |                               | TC         | AG         | CT         | TG        | GA        |
| 30          | NR       | 70         | F          | 3       | 4.78 | 8.1   |                               | TC         | AG         | CT         | TG        | GA        |
| 31          | TR       | 62         | F          | 3       | 3.53 | 14.0  |                               | TC         | AG         | CT         | TG        | GA        |
| 32          | NR       | 56         | M          | 4       | 7.37 | 30.8  |                               | CC         | GG         | TT         | GG        | AA        |

NOTE. The Pearson correlation of the  $r^2$  estimates for adjacent pairs; rs8099917 vs rs8105790, rs8099917 vs rs11881222, rs8099917 vs rs12979860, and rs8099917 vs rs7248668 = 0.99, 0.99, 0.98, and 0.97, respectively. IL28B, interleukin 28B; GWAS, genome-wide association studies; ISGs, interferon stimulated genes; SNP, single nucleotide polymorphism; SVR, sustained viral response; TR, transient response; NR, no response; M, male; F, female.

To examine further the different hepatic gene expression of patients with the major or minor genotypes, pathway analysis of differentially expressed genes between the 2 groups was performed. By comparing the expression of hepatic genes between patients with the major and minor genotypes, 1359 differentially expressed genes were identified ( $P < .01$ ; 711 genes were up-regulated with the minor genotype, and 648 genes were up-regulated with the major genotype). Pathway analysis of these genes demonstrated that signaling pathways related to interferon action, apoptosis, and Wnt signaling were up-regulated in the liver of patients with the minor genotype, whereas B-cell-, dendritic cell-, and natural killer cell-related genes were up-regulated in the liver of patients with the major genotype (Supplementary Figure 3). These results suggest that IL28B may be involved in innate and adaptive immune responses and that different antiviral signaling pathways might be involved in the liver of patients with different SNPs.

### Discussion

Multiple viral and host factors may be related to the treatment response to Peg-IFN and RBV combination therapy. For the viral factors, a higher number of aa substitutions in the ISDR of nonstructural 5A region was strongly associated with a favorable response to IFN- $\alpha$  monotherapy in patients with genotype-1 HCV.<sup>4</sup>

Besides viral factors, host factors such as age, gender, fibrotic stage of the liver, and the presence of steatosis and insulin resistance were associated with the treatment outcome.<sup>20</sup> Analysis of hepatic gene expression demonstrated that the up-regulation of ISGs in the liver before treatment may be related to a poor treatment response.<sup>6-9</sup> To reveal the underlying mechanism of treatment resistance, 2 reports compared gene expression profiling in the liver before and during therapy and showed that patients with up-regulated ISGs in the liver prior to treatment failed to further induce ISGs following the ad-



**Table 4.** Comparison of Clinical Factors Between Patients With Major (TT) and Minor (TG+GG) Alleles


| Clinical category                         | TT          |               | TG+GG      |             | Univariate<br><i>P</i> value | Multivariate odds<br>(95% CI) | Multivariate<br><i>P</i> value |
|---|-------------|---------------|------------|-------------|------------------------------|-------------------------------|--------------------------------|
| No. of patients                           | n = 60      |               | n = 31     |             |                              | —                             |                                |
| Treatment response                        |             |               |            |             |                              |                               |                                |
| SVR+TR vs NR                              | 51 vs 9     |               | 11 vs 20   |             | <.001                        | —                             |                                |
| Age and gender                            |             |               |            |             |                              |                               |                                |
| Age, y                                    | 56          | (30–69)       | 56         | (30–71)     | .843                         | —                             |                                |
| Sex (M vs F)                              | 39 vs 21    |               | 19 vs 12   |             | .518                         | —                             |                                |
| Liver factors                             |             |               |            |             |                              |                               |                                |
| F stage (F1-2 vs F3-4)                    | 36 vs 24    |               | 23 vs 17   |             | .905                         | —                             |                                |
| A grade (A0-1 vs A2-3)                    | 27 vs 33    |               | 20 vs 11   |             | .075                         | —                             |                                |
| ISGs (Mx, IFI44, IFIT1)<br>(<3.5 vs ≥3.5) | 46 vs 14    |               | 5 vs 26    |             | <.001                        | 18.1 (3.95–113)               | <.001                          |
| Laboratory parameters                     |             |               |            |             |                              |                               |                                |
| HCV-RNA (KIU/mL)                          | 2055        | (160–5000)    | 1970       | (126–5000)  | .602                         | —                             |                                |
| BMI (kg/m <sup>2</sup> )                  | 24.5        | (16.3–40.5)   | 22.9       | (19.1–26.6) | .006                         | —                             | .077                           |
| AST (IU/L)                                | 59          | (22–258)      | 54         | (21–283)    | .227                         | —                             |                                |
| ALT (IU/L)                                | 75          | (24–376)      | 60         | (18–236)    | .077                         | —                             |                                |
| γ-GTP (IU/L)                              | 61          | (4–392)       | 53         | (20–229)    | .517                         | —                             | .167                           |
| WBC (/mm <sup>3</sup> )                   | 4450        | (2100–11,100) | 4600       | (2500–8200) | .947                         | —                             |                                |
| Hb (g/dL)                                 | 14.2        | (11.4–16.7)   | 14.5       | (11.2–17.2) | .606                         | —                             |                                |
| PLT (×10 <sup>4</sup> /mm <sup>3</sup> )  | 15.4        | (7–39.4)      | 16.2       | (9.2–27.7)  | .832                         | —                             |                                |
| TG (mg/dL)                                | 98          | (58–248)      | 131        | (30–303)    | .053                         | —                             | .055                           |
| T-Chol (mg/dL)                            | 172         | (115–222)     | 168        | (129–237)   | .910                         | —                             |                                |
| LDL-Chol (mg/dL)                          | 84          | (42–123)      | 69         | (51–107)    | .052                         | —                             | .055                           |
| HDL-Chol (mg/dL)                          | 44          | (18–72)       | 45         | (29–77)     | .218                         | —                             |                                |
| FBS (mg/dL)                               | 95          | (59–291)      | 96         | (66–206)    | .849                         | —                             |                                |
| Insulin (μU/mL)                           | 7.5         | (0.7–23.2)    | 9.2        | (2–23.2)    | .195                         | —                             |                                |
| HOMA-IR                                   | 1.3         | (0.3–11.7)    | 1.2        | (0.4–9.6)   | .339                         | —                             |                                |
| Viral factors                             |             |               |            |             |                              |                               |                                |
| ISDR mutations (≤1 vs ≥2)                 | 38 vs 22    |               | 23 vs 7    |             | .194                         | —                             | .083                           |
| Treatment factors                         |             |               |            |             |                              |                               |                                |
| Total dose administrated                  |             |               |            |             |                              |                               |                                |
| Peg-IFN (μg)                              | 3960        | (1500–7200)   | 3840       | (1920–5760) | .377                         | —                             |                                |
| RBV (g)                                   | 203         | (26–336)      | 201        | (106–268)   | .777                         | —                             |                                |
| Achieved administration rate              |             |               |            |             |                              |                               |                                |
| Peg-IFN (%)                               |             |               |            |             |                              |                               |                                |
| ≥80%                                      | 41          |               | 17         |             | .207                         | —                             |                                |
| <80%                                      | 19          |               | 14         |             |                              |                               |                                |
| RBV (%)                                   |             |               |            |             |                              |                               |                                |
| ≥80%                                      | 34          |               | 19         |             | .671                         | —                             |                                |
| <80%                                      | 26          |               | 12         |             |                              |                               |                                |
| Achievement of EVR                        | 40/60 (62%) |               | 9/31 (29%) |             | <.001                        | —                             |                                |

BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IFI44, interferon-induced protein 44; IFIT1, interferon-induced protein with tetratricopeptide repeats 1; EVR, early virologic response; γ-GTP, γ-glutamyl transpeptidase; ISDR, interferon sensitivity determining region; Mx1, myxovirus (influenza virus) resistance 1 interferon-inducible protein p78 (mouse); WBC, leukocytes; HOMA-IR, homeostasis model assessment of insulin resistance; Hb, hemoglobin; RBV, ribavirin; PLT, platelets; TG, triglycerides; TR, transient response; T-chol, total cholesterol; LDL-chol, low-density lipoprotein cholesterol; HDL-chol, high-density lipoprotein cholesterol; FBS, fasting blood sugar; CI, confidence interval.

ministration of IFN and could not eliminate HCV.<sup>6,7</sup> We performed a similar analysis and observed that these findings were more evident in liver lobular cells than in infiltrating lymphocytes in the portal area (submitted for publication). Thus, both viral and host factors might be closely related to the treatment response to Peg-IFN and RBV combination therapy. However, the clinical relevance and relationships of these factors have not been fully evaluated. In this study, we validated the clinical significance of the expression of hepatic ISGs on treatment outcome using a relatively large cohort of patients and com-

pared its significance with other viral and host factors. To compare the patients with SVR, TR, and NR, we assessed the overall plausibility of each group using Fisher C statistic,<sup>16</sup> and patients with SVR and TR were grouped together for further analysis.

We examined hepatic gene expression in 91 of 168 patients using the Affymetrix genechip. Expression profiling using 37 representative ISGs (see Materials and Methods), which were selected from gene expression profiling comparing pretreatment and under treatment liver, differentiated 2 groups of



**Figure 2.** Hierarchical clustering analysis of 91 patients with the defined genotype of IL28B. Responses to therapy (SVR, TR, and NR) and IL28B genotype (TT, TG, or GG) are shown. The structure of the dendrogram and heat map is the same as in Figure 1.

patients: the Up-ISG and Down-ISG groups (Figure 1). The proportion of patients with NR to treatment was significantly higher in the Up-ISGs group.

Multivariate analysis showed that hepatic ISGs (<3.5), fibrosis stage (F1-F2), and ISDR mutations ( $\geq 2$ ) significantly contributed to the outcome for the SVR+TR group (Table 1). Discriminate analysis using variables selected by multivariable analysis predicted the SVR+TR patients with 82% accuracy and NR patients with 79% accuracy. However, the accuracy decreased to 67% for SVR+TR patients and 53% for NR patients when the expression of hepatic ISGs was removed from the variables (data not shown). Interestingly, the expression of hepatic ISGs was strongly correlated with  $\gamma$ -GTP and weakly correlated with insulin resistance. A recent study describing the association between insulin resistance and poor treatment outcome might be partially explained by this observation.<sup>20</sup>


In this study, we utilized 3 ISGs (Mx1, IFI44, and IFIT1) out of 15 validated by RTD-PCR. The expression values of these ISGs were higher than those of other ISGs (Supplementary Figure 1A). We averaged these ISGs and set the cut-off value as 3.5 from the ROC curve (Supplementary Figure 1B). The sensitivity, specificity, and positive and negative predictive values on the likelihood of achieving SVR+TR using this cut-off value were 82% (103/125), 72% (31/43), 90% (103/115), and 58% (31/53), respectively. The results were compared with those observed for the 15 ISGs (Supplementary Table 5). These results showed that the 3.5 cut-off value for Mx1, IFI44, and IFIT1 would be valuable for clinical use.

Despite the importance of the expression of hepatic ISGs, viral factors may also allow us to predict the outcome of treatment. Multivariate analysis showed that ISDR mutations

( $\geq 2$ ) independently contributed to the treatment outcome, although univariate analysis did not show significance ( $P = .07$ ); therefore, ISDR might be uniquely and differentially involved in treatment resistance.

What causes the differences in the expression of hepatic ISGs? In parallel to the gene expression analysis, a GWAS was applied to identify genomic loci associated with treatment response, and a polymorphism in IL28B was found to predict hepatitis C treatment-induced viral clearance.<sup>10-12</sup> To examine the relationship between the genetic variation of IL28B and hepatic gene expression, we determined the IL28B polymorphism in 91 patients (Table 3). The patients with the minor genotype (TG or GG) had an increased expression of hepatic ISGs compared with the patients with major genotype (TT) (Figures 2 and 3). In European-Americans, the proportion of major homozygotes is 39% (CC at rs1297986), 49% for heterozygotes (TC), and 12% for minor homozygotes (TT).<sup>11</sup> Although the proportion of minor homozygotes was much less in this study (GG, 4%), as reported in a previous study in Japan,<sup>12</sup> more patients are required for proper evaluation. It is interesting that the expression of hepatic ISGs in minor homozygotes (GG) was higher than in heterozygotes (TG) in this study.

The results clearly showed that the differences in the expression of hepatic ISGs before treatment are associated with the IL28B polymorphism and results in different treatment outcomes. Although we could not detect significant differences in the expression levels of IL28B depending on the different SNP, some patients with the major genotype showed a higher expression of IL28B. Because IL28B expression was approximately 10-fold less than the expression of ISGs, the lower



**Figure 3.** (A) IL28B expression in the liver of 91 patients with the major (TT) or minor (TG or GG) genotype (rs8099917). (B) Expression of ISGs in the liver of patients with the major (TT) or minor (TG or GG) genotype (rs8099917). (C) Relationship between IL28B and ISGs in the liver of patients with the major (TT) genotype (rs8099917). (D) Relationship between IL28B and ISGs in the liver of patients with the minor (TG or GG) genotype (rs8099917).

expression of IL28B may be a reason for the decreased ability to distinguish differences in its expression. Another possibility may be the specificity of the IL28B primers used in this study; because IL28B shares a 98.2% nucleotide sequence homology with IL28A, IL28B specific primers are not available.<sup>21</sup> When the expression of IL28B and hepatic ISGs were compared, a significant correlation was observed, and, interestingly, IL28B and ISGs derived from different SNPs were correlated in a different way (Figure 3C and D). It appeared that hepatic ISGs were more induced by the reduced amounts of IL28B in patients with the minor genotype. The mechanism behind these findings has yet to be determined; however, IL28B interacts with a heterodimeric class II cytokine receptor that consists of IL-10 receptor  $\beta$  (IL-10R $\beta$ ) and IL-28 receptor  $\alpha$  (IL-28R $\alpha$ ).<sup>18,19</sup> It is possible that IL28B could mediate antiviral signaling through IL-10 signaling as well as STAT1 activation. The Th 2 dominant signaling of IL28B may modulate signaling pathways in livers with CH-C and contributes to the different expression of ISGs. Another possibility may be that the cell origin of hepatic ISGs is different. A recent study revealed cell-type specific ISG expression in macrophages and hepatocytes, which could be related to the IFN response.<sup>22</sup> As more of the B-cell-, dendritic cell-, and natural killer cell-related genes were up-regulated in the liver of patients with the major genotype, ISGs could be expressed by these cells, whereas they are expressed by hepatocytes in the liver of patients with the minor genotype. It is known that the

induction of ISGs in lymphocytes is lower than that in hepatocytes. The precise mechanism should be investigated further as a different regulatory mechanism for the expression of ISGs may be present.

In conclusion, we presented the clinical relevance of the expression of hepatic ISGs for the treatment outcome of Peg-IFN and RBV combination therapy. The different expressions of hepatic ISGs before treatment might be due to polymorphisms in IL28B. Further studies are required to clarify the detailed pathways of IL28B and hepatic gene expression through molecular biologic and immunologic aspects.

### Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of *Gastroenterology* at [www.gastrojournal.org](http://www.gastrojournal.org), and at doi: 10.1053/j.gastro.2010.04.049.

### Appendix 1. The Hokuriku Liver Study Group (HLSG) is Composed of the Following Members:

Drs Takashi Kagaya, Kuniaki Arai, Kaheita Kakinoki, Kazunori Kawaguchi, Hajime Takatori, Hajime Sunakosaka (Department of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa); Drs Touru

Nakahama, Shinji Kamiyamamoto (Kurobe City Hospital, Kurobe, Toyama); Dr Yasuhiro Takemori (Toyama Rosai Hospital, Uozu, Toyama); Dr Hikaru Oguri (Koseiren Namerikawa Hospital, Namerikawa, Toyama); Drs Yatsugi Noda, Hidero Ogino (Toyama Prefectural Central Hospital, Toyama, Toyama); Drs Yoshinobu Hinoue, Keiji Minouchi (Toyama City Hospital, Toyama, Toyama); Dr Nobuyuki Hirai (Koseiren Takaoka Hospital, Takaoka, Toyama); Drs Tatsuho Sugimoto, Koji Adachi (Tonami General Hospital, Tonami, Toyama); Dr Yuichi Nakamura (Noto General Hospital, Nanao, Ishikawa); Drs Masashi Unoura, Ryuhei Nishino (Public Hakui Hospital, Hakui, Ishikawa); Drs Hideo Morimoto, Hajime Ohta (National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa); Dr Hirokazu Tsuji (Kanazawa Municipal Hospital, Kanazawa, Ishikawa); Drs Akira Iwata, Shuichi Terasaki (Kanazawa Red Cross Hospital, Kanazawa, Ishikawa); Drs Tokio Wakabayashi, Yukihiro Shirota (Saiseikai Kanazawa Hospital, Kanazawa, Ishikawa); Drs Takeshi Urabe, Hiroshi Kawai (Public Central Hospital of Matto Ishikawa, Hakusan, Ishikawa); Dr Yasutsugu Mizuno (Nomi Municipal Hospital, Nomi, Ishikawa); Dr Shoni Kameda (Komatsu Municipal Hospital, Komatsu, Ishikawa); Drs Hirotohi Miyamori, Uichiro Fuchizaki (Keiju Medical Center, Nanao, Ishikawa); Dr Haruhiko Shyugo (Kanazawa Arimatsu Hospital, Kanazawa, Ishikawa); Dr Hideki Osaka (Yawata Medical Center, Komatsu, Ishikawa); Dr Eiki Matsushita (Kahoku Central Hospital, Tsubata, Ishikawa); Dr Yasuhiro Katou (Katou Hospital, Komatsu, Ishikawa); Drs Nobuyoshi Tanaka, Kazuo Notsumata (Fukuiken Saiseikai Hospital, Fukui, Fukui); Dr Mikio Kumagai (Kumagai Clinic, Tsuruga, Fukui); Dr Manabu Yoneshima (Municipal Tsuruga Hospital, Tsuruga, Fukui).

## References

- Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. *Hepatology* 1990;12:671–675.
- Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;347:975–982.
- Poynard T, Ratzliff V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. *Hepatology* 2003;38:75–85.
- Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the non-structural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 1996;334:77–81.
- Okanoue T, Itoh Y, Hashimoto H, et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. *J Gastroenterol* 2009;44:952–963.
- Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. *Hepatology* 2007;46:1548–1563.
- Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. *Proc Natl Acad Sci U S A* 2008;105:7034–7039.
- Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. *Gut* 2008;57:516–524.
- Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. *Gastroenterology* 2005;128:1437–1444.
- Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature* 2009;461:798–801.
- Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 2009;461:399–401.
- Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon- $\alpha$  and ribavirin therapy for chronic hepatitis C. *Nat Genet* 2009;41:1105–1109.
- Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology* 1994;19:1513–1520.
- Honda M, Yamashita T, Ueda T, et al. Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C. *Hepatology* 2006;44:1122–1138.
- Honda M, Kaneko S, Kawai H, et al. Differential gene expression between chronic hepatitis B and C hepatic lesion. *Gastroenterology* 2001;120:955–966.
- Shipley B. A new inferential test for path models based on directed acyclic graphs. *Structural Equation Modeling* 2000;7:206–218.
- Favre M, Martin J, Festa-Bianchet M. Determinants and life-history consequences of social dominance in bighorn ewes. *Anim Behav* 2008;76:1373–1380.
- Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29, and their class II cytokine receptor IL-28R. *Nat Immunol* 2003;4:63–68.
- Kotenko SV, Gallagher G, Baurin VV, et al. IFN- $\lambda$  mediate antiviral protection through a distinct class II cytokine receptor complex. *Nat Immunol* 2003;4:69–77.
- Camma C, Bruno S, Di Marco V, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. *Hepatology* 2006;43:64–71.
- Mihm S, Frese M, Meier V, et al. Interferon type I gene expression in chronic hepatitis C. *Lab Invest* 2004;84:1148–1159.
- Chen L, Borozan I, Sun J, et al. Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. *Gastroenterology* 2010;138:942–948.

---

Received October 9, 2009. Accepted April 14, 2010.

### Reprint requests

Address requests for reprints to: Shuchi Kaneko, MD, PhD, Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Takara-Machi 13-1, Kanazawa 920-8641, Japan. e-mail: skaneko@m-kanazawa.jp; fax: (81) 76-234-4250.

### Acknowledgments

The authors thank Nami Nishiyama and Yuki Hatayama for excellent technical assistance.

Participating investigators are listed in Appendix 1.

### Conflicts of interest

The authors disclose no conflicts.

### Funding

This work was supported in part by a grant-in-aid from the Ministry of Health, Labour and Welfare of Japan.

Endoscopic naso-pancreatic drainage for the treatment of pancreatic fistula occurring after living donor liver transplantation

Running title: Endoscopic naso-pancreatic drainage for pancreatic fistula after liver transplantation

Akihisa Nagatsu, Masahiko Taniguchi, Tsuyoshi Shimamura, Tomomi Suzuki, Kenichiro Yamashita, Hiroshi Kawakami, Daisuke Abo, Toshiya Kamiyama, Hiroyuki Furukawa, Satoru Todo

**Akihisa Nagatsu, Toshiya Kamiyama, Satoru Todo**, Department of General Surgery, Graduate School of Medicine, Hokkaido University, N-15 W-7, Kita-ku, Sapporo 060-8638, JAPAN.

**Masahiko Taniguchi, Tomomi Suzuki, Hiroyuki Furukawa**, Department of Organ Transplantation and Regeneration, Graduate School of Medicine, Hokkaido University, N-15 W-7, Kita-ku, Sapporo 060-8638, JAPAN.

**Tsuyoshi Shimamura**, Division of Organ Transplantation, Graduate School of Medicine, Hokkaido University, N-15 W-7, Kita-ku, Sapporo 060-8638, JAPAN.

**Kenichiro Yamashita**, Department of Molecular Surgery, Graduate School of Medicine, Hokkaido University, N-15 W-7, Kita-ku, Sapporo 060-8638, JAPAN.

**Hiroshi Kawakami**, Department of Gastroenterology, Graduate School of Medicine, Hokkaido University, N-15 W-7, Kita-ku, Sapporo 060-8638, JAPAN.

**Daisuke Abo**, Department of Radiology, Graduate School of Medicine, Hokkaido University, N-15 W-7, Kita-ku, Sapporo 060-8638, JAPAN.

Author contributions: Nagatsu A contributed to this work mainly; Nagatsu A, Taniguchi M, Shimamura T, Suzuki T, Yamashita K, Kamiyama T, Furukawa H, Todo S, Kawakami H and Abo D provided medical care; Nagatsu A and Taniguchi M wrote the paper.

Correspondence to: Taniguchi M, MD, Department of Organ Transplantation and Regeneration, Graduate School of Medicine, Hokkaido University, N-15 W-7, Kita-ku, Sapporo 060-8638, JAPAN. [tonny@isis.ocn.ne.jp](mailto:tonny@isis.ocn.ne.jp)

## ABSTRACT

Pancreatic fistula is a quite rare complication in patients who undergo living donor liver transplantation (LDLT). However, in the cases that show pancreatic

fistula, the limited volume of the graft and the resultant inadequate liver function may complicate the management of the fistula. As a result, pancreatic fistula may result in the death of the patient. We present 2 cases in which endoscopic treatment was effective against pancreatic fistulas that developed after LDLT. In case 1, a 61-year-old woman underwent LDLT for primary biliary cirrhosis. Because of a portal venous thrombus caused by a splenorenal shunt, the patient underwent portal vein reconstruction, and a splenorenal shunt was ligated on postoperative day (POD) 7. The main pancreatic duct was injured during the manipulation to achieve hemostasis, thereby necessitating open drainage. However, discharge of pancreatic fluid continued even after POD 300. Endoscopic naso-pancreatic drainage (ENPD) was performed, and this procedure resulted in a remarkable decrease in drain output. The refractory pancreatic fistula healed on day 40 after ENPD. In case 2, a 58-year-old man underwent LDLT for cirrhosis caused by the hepatitis C virus. When the portal vein was exposed during thrombectomy, the pancreatic head was injured, which led to the formation of a pancreatic fistula. Conservative therapy was ineffective; therefore, ENPD was performed. The pancreatic fistula healed on day 38 after ENPD. The findings in these 2 cases show that endoscopic drainage

of the main pancreatic duct is a less invasive and effective treatment for pancreatic fistulas that develop after LDLT.

Key words: pancreatic fistula, endoscopic treatment, living donor liver transplantation, complications.

## INTRODUCTION

The incidence of complications associated with living donor liver transplantation (LDLT) is known to be greater than that associated with deceased donor liver transplantation (DDLT)<sup>[1-4]</sup>. In the patients who undergo LDLT, the incidence of complications, including mild complications, during the perioperative period can be as high as 82.8%. In particular, the rate of development of biliary complications after LDLT is twice of that after DDLT<sup>[1]</sup>. Moreover, patients who undergo LDLT often have inadequate liver function because of the limited volume of the graft. Therefore, the management of complications is very difficult, and the mortality rate in critical cases is high.

Compared to other abdominal surgery, pancreatic fistula is a quite rare complication after LDLT<sup>[1-5]</sup>, but it is theoretically possible because LDLT



involves surgery in the area surrounding the portal vein, the pancreas, and the spleen. Pancreatic fistula causes hemorrhage, abscess, etc., and may result in the death of the patient<sup>[6-8]</sup>. Only 1 previous study has reported 2 cases of leakage of pancreatic fluid after liver transplantation. In those cases, leakage of a mixture of pancreatic fluid and bile was observed at the anastomosis site of the bile duct after DDLT<sup>[9]</sup>. However, there is no clear consensus on the management of pancreatic fistula after liver transplantation. Generally, conservative therapy is the first line of treatment, and surgery is performed only when the patient does not respond to conservative therapy<sup>[6-8]</sup>. Recently, however, endoscopic treatment has attracted more attention because it is less invasive than surgical treatment. We present 2 cases in which endoscopic treatment was effective against refractory pancreatic fistulas that developed after LDLT.

## CASE REPORTS

### *Case 1*

A 61-year-old woman underwent LDLT for primary biliary cirrhosis; the graft was obtained from the left liver lobe of her son. Abdominal computed tomography (CT) performed on postoperative day (POD) 7 revealed a portal

vein thrombus; therefore, urgent exploratory laparotomy was performed. The thrombus was believed to have been induced by reduced portal blood flow, which was caused by splenorenal steal by an artificial shunt. After removing the thrombus, portal vein reconstruction was performed by using the right external iliac vein, and this procedure was followed by splenectomy. To increase the portal blood flow, a splenorenal shunt was ligated. The main pancreatic duct on the dorsal side of the pancreas was injured at the time of hemostatic manipulation; however, this injury was not identified immediately. CT performed on POD 13 revealed a hematoma at the lower edge of the pancreas. CT on POD 21 revealed that the hematoma under the pancreas had decreased in size (fig 1). The amylase level of the drainage fluid was 22690 IU/l; therefore, the hematoma at the inferior edge of the pancreas was considered to have ruptured because of a pancreatic leak. Another CT examination revealed fluid collection in the mesentery on the ventral side of the upper pole of the left kidney; therefore, open drainage was performed. To this end, a drain was placed at the tail of the pancreas and administration of octreotide was started. However, the leakage of pancreatic fluid from the drain did not stop. After several days, the patient's general status stabilized, but surgical treatment for

pancreatic fistula was still unsafe because of inadequate liver function. Therefore, the patient was discharged on POD 128 with the drain in place and was followed up. The patient was in a stable state at discharge. However, on POD 318, she was readmitted to our department because of fever. Examinations revealed that the drain at the tail of the pancreas had deviated and that the patient had developed liver necrosis, supposedly because of contact with the drain. On POD 320, we repositioned the drain by using a fluoroscope. A contrast test performed at that time revealed that the main pancreatic duct was completely disrupted (fig 2). The patient was diagnosed with refractory pancreatic fistula, and an endoscopic naso-pancreatic drainage (ENPD) tube was inserted to the proximal side of the leakage on POD 331 (fig 3); this procedure resulted in a remarkable decrease in drain output (fig 4) (fig 5). The ENPD tube was removed on POD 368, and the drains at the tail of the pancreas were removed on POD 371. The patient was discharged on POD 375 without abnormal fluid collection around the pancreas (fig 6). The patient is well without the recurrence of pancreatic fistula up to this time.

## *Case 2*

A 58-year-old man underwent LDLT for cirrhosis C; the graft was obtained from the right liver lobe of his daughter. Because the portal vein was occluded by a thrombus, the portal and splenic veins were stripped off from the surrounding tissue and were exposed in order to remove the thrombus. However, the upper edge of the pancreatic head was injured during this process. The amylase level measured at the upper edge of the pancreatic drain was high on POD 1; therefore, the patient received octreotide on POD 2. On POD 5, the patient showed high fever and acute peritonitis. Therefore, an emergency exploratory laparotomy was performed. Because fluid collection was observed around the pancreas, drains were placed at both the right and left edges of the pancreas. On POD 21, the total output from the drain was 460 ml/day, and the amylase level of the drainage fluid was 166700 IU/l. The patient was diagnosed with high-output pancreatic fistula, and ENPD was performed on POD 22 (fig 7). The drain output decreased very rapidly (fig 8); therefore, the patient was allowed to consume solid foods on POD 49, and octreotide administration was stopped on POD 50. The ENPD tube was removed on POD 65, and the drains placed at the right and left edges of the pancreas were removed on POD 68 and POD 70, respectively. The patient was